Naropin (ropivacaine hydrochloride Injection, USP), 0.5%,… was recalled on July 16, 2026 in cooperation with the U.S. Food and Drug Administration because presence of Particulate Matter: Hair was found in products.
Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-05
Lot #: 6133436, Exp. Date 10/2028
Units affected: 92,600 vials
Where it was sold: Nationwide within in the USA
Compare the codes above against the label on your product — usually on the bottom, the back panel, or the packaging. If your unit isn't listed, it is not part of this recall.
Presence of Particulate Matter: Hair was found in products
Class II means the product might cause a temporary or medically reversible health problem; the chance of serious harm is remote.
Stop using the product. Return it to the place of purchase for a refund, or dispose of it. Contact the recalling firm with questions.
Contact: Recalling firm: Fresenius Kabi USA, LLC
Not sure what you're entitled to? Read our guide: what to do if your product is recalled.
Always confirm details on the official notice from the U.S. Food and Drug Administration before acting.
View official notice →The recalled doll playsets violate the small parts ban because the toys are for children under three years old and some of the accessories are small parts, posing a deadly choking hazard.
The recalled sweaters violate the mandatory standard for clothing textiles, posing a risk of serious burn injuries or death.
Presence of Particulate Matter: Hair was found in products
Presence of Particulate Matter: Hair was found in products
Be the first to know when products like this are recalled. Free weekly digest, unsubscribe anytime.